Literature DB >> 12388676

Renal disposition of a furan dicarboxylic acid and other uremic toxins in the rat.

Yasuhiro Tsutsumi1, Tsuneo Deguchi, Mikihisa Takano, Akira Takadate, W Edward Lindup, Masaki Otagiri.   

Abstract

The aim of this study was to understand the mechanisms that underlie the renal elimination of albumin-bound uremic toxins, particularly the highly bound furan acid 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), that accumulate in chronic renal failure. These toxins inhibit the binding of acidic drugs and have various other untoward effects. The pharmacokinetics and tissue distribution of CMPF plus three other such toxins, indoxyl sulfate, indole acetic acid, and hippuric acid, have been examined in the anesthetized rat. The effects of p-aminohippuric (PAH) acid and tetraethylammonium on the uptake of CMPF by rat renal cortical slices in vitro were also investigated to characterize its mechanism of uptake. Plasma and tissue concentrations of the uremic toxins were determined by high-performance liquid chromatography. The rate of elimination of the toxins from plasma was indoxyl sulfate > hippuric acid > indole acetic acid > CMPF. Although the renal clearance of CMPF was low, its main elimination pathway was via urinary excretion with active tubular secretion. In renal cortical slice experiments, mutual inhibition between CMPF and PAH was observed. In addition, alpha-ketoglutarate stimulated the uptake of CMPF by renal cortical slices. The base tetraethylammonium did not inhibit slice uptake of CMPF. The pharmacokinetics of CMPF was characterized by slow plasma clearance and localization in the kidney. Furthermore, the evidence from experiments with renal cortical slices indicates that the uptake of CMPF is mediated by an anion/dicarboxylate exchanger, similar to that for PAH.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388676     DOI: 10.1124/jpet.303.2.880

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Differential contributions of rOat1 (Slc22a6) and rOat3 (Slc22a8) to the in vivo renal uptake of uremic toxins in rats.

Authors:  Tsuneo Deguchi; Yousuke Kouno; Tetsuya Terasaki; Akira Takadate; Masaki Otagiri
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

2.  Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney.

Authors:  Harunobu Tahara; Masayuki Shono; Hiroyuki Kusuhara; Hajime Kinoshita; Eiichi Fuse; Akira Takadate; Masaki Otagiri; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

3.  Tubular Secretion in CKD.

Authors:  Astrid M Suchy-Dicey; Thomas Laha; Andrew Hoofnagle; Rick Newitt; Tammy L Sirich; Timothy W Meyer; Ken E Thummel; N David Yanez; Jonathan Himmelfarb; Noel S Weiss; Bryan R Kestenbaum
Journal:  J Am Soc Nephrol       Date:  2015-11-27       Impact factor: 10.121

4.  Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.

Authors:  H Sun; L A Frassetto; Y Huang; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

5.  A reference map of potential determinants for the human serum metabolome.

Authors:  Noam Bar; Tal Korem; Omer Weissbrod; David Zeevi; Daphna Rothschild; Sigal Leviatan; Noa Kosower; Maya Lotan-Pompan; Adina Weinberger; Caroline I Le Roy; Cristina Menni; Alessia Visconti; Mario Falchi; Tim D Spector; Jerzy Adamski; Paul W Franks; Oluf Pedersen; Eran Segal
Journal:  Nature       Date:  2020-11-11       Impact factor: 49.962

6.  An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure.

Authors:  Kazuki Shimoishi; Makoto Anraku; Kenichiro Kitamura; Yuka Tasaki; Kazuaki Taguchi; Mitsuru Hashimoto; Eiko Fukunaga; Toru Maruyama; Masaki Otagiri
Journal:  Pharm Res       Date:  2007-03-27       Impact factor: 4.580

7.  False-negative diagnosis of high anion gap in patients with end-stage kidney disease.

Authors:  You Komatsuzaki; Masato Ikeda; Akihiro Shimizu; Nanae Matsuo; Yukio Maruyama; Takashi Yokoo; Hiroyuki Yamamoto; Nobuhiko Joki; Ryoichi Ando; Daijo Inaguma; Toshihiko Yamaka; Masaaki Nakayama; Fumihiko Koiwa; Shinya Kawamoto; Shigeo Negi; Takashi Shigematsu
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

8.  Distinct metabolic profile of primary focal segmental glomerulosclerosis revealed by NMR-based metabolomics.

Authors:  Xu Hao; Xia Liu; Weiming Wang; Hong Ren; Jingyuan Xie; Pingyan Shen; Donghai Lin; Nan Chen
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

9.  Increased serum 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) levels are associated with glucose metabolism in Chinese pregnant women.

Authors:  J Yi; H Jin; R Zhang; S Zhang; P Chen; X Yu; X Zhang
Journal:  J Endocrinol Invest       Date:  2017-11-18       Impact factor: 4.256

10.  Serum metabolomics approach to monitor the changes in metabolite profiles following renal transplantation.

Authors:  Ivana Stanimirova; Mirosław Banasik; Adam Ząbek; Tomasz Dawiskiba; Katarzyna Kościelska-Kasprzak; Wojciech Wojtowicz; Magdalena Krajewska; Dariusz Janczak; Piotr Młynarz
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.